Editorial commentary: How to implement research studies on extracellular vesicle administration in myocardial infarction

Myocardial infarction (MI) remains one of the leading causes of death worldwide. Although treatments to reduce myocardial damage during MI are continuously improving, no therapy capable of remarkably inducing myocardial regeneration is currently avail- able for clinical use. For these reasons, a highly active area of re- search in the cardiovascular field is focused on the development of innovative therapies for cardiac repair after MI in order to reduce the subsequent incidence of heart failure (HF). Among the ap- proaches being studied, the potential beneficial pleiotropic effects elicited by extracellular vesicles (EVs) are particularly fascinating.